J. Crofton, The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line, J R Soc Med, vol.99, issue.10, p.17021304, 2006.

. Medical-research and . Council, Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation, Br Med J, vol.2, issue.4582, p.18890300, 1948.

W. Fox, I. Sutherland, and M. Daniels, A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council, Q J Med, vol.23, issue.91, p.13194851, 1954.

C. S. Merle, K. Fielding, O. B. Sow, M. Gninafon, M. B. Lo et al., A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis, N Engl J Med, vol.371, issue.17, pp.1588-98, 2014.

A. Jindani, T. S. Harrison, A. J. Nunn, P. P. Phillips, G. J. Churchyard et al., High-dose rifapentine with moxifloxacin for pulmonary tuberculosis, N Engl J Med, vol.371, issue.17, p.4233406, 2014.

S. H. Gillespie, A. M. Crook, T. D. Mchugh, C. M. Mendel, S. K. Meredith et al., Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis, N Engl J Med, vol.371, issue.17, pp.1577-87, 2014.

J. L. Johnson, D. J. Hadad, R. Dietze, E. L. Maciel, B. Sewali et al., Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion, Am J Respir Crit Care Med, vol.180, issue.6, pp.558-63, 2009.

P. Central and P. , , p.2742745

S. Hopewell, M. Clarke, L. Stewart, and J. Tierney, Time to publication for results of clinical trials, Cochrane Database Syst Rev, issue.2, p.17443632, 2007.

K. Dheda, T. Gumbo, G. Maartens, K. E. Dooley, R. Mcnerney et al., The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis, Lancet Respir Med, vol.5, issue.4, 2017.

C. C. Boehme, M. P. Nicol, P. Nabeta, J. S. Michael, E. Gotuzzo et al., diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study, Lancet, vol.377, issue.9776, p.3085933, 2011.

M. Barnard, H. Albert, G. Coetzee, R. O'brien, and M. E. Bosman, Rapid molecular screening for multidrugresistant tuberculosis in a high-volume public health laboratory in South Africa, Am J Respir Crit Care Med, vol.177, issue.7, p.18202343, 2008.

, World Health Organization, Foundation for Innovative New Diagnostics. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2018.

A. Van-deun, A. Maug, M. Salim, P. K. Das, M. R. Sarker et al., Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis, Am J Respir Crit Care Med, vol.182, issue.5, p.20442432, 2010.

. Endtb-study-group, Bedaquiline-and delamanid-containing regimens achieve excellent interim treatment response without safety concerns: endTB interim analysis, 2018.

K. Schnippel, N. Ndjeka, G. Maartens, G. Meintjes, I. Master et al., Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study, Lancet Respir Med, vol.6, issue.9, p.30001994, 2018.

K. J. Aung, A. Van-deun, E. Declercq, M. R. Sarker, P. K. Das et al., Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients, Int J Tuberc Lung Dis, vol.18, issue.10, p.25216831, 2014.

C. Lienhardt, M. Raviglione, M. Spigelman, R. Hafner, E. Jaramillo et al., New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future, J Infect Dis, vol.205, issue.2, pp.241-250, 2012.

N. S. Shah, S. C. Auld, J. C. Brust, B. Mathema, N. Ismail et al., Transmission of Extensively DrugResistant Tuberculosis in South Africa, N Engl J Med, vol.376, issue.3, p.5330208, 2017.

E. S. Mcbryde, M. T. Meehan, T. N. Doan, R. Ragonnet, B. J. Marais et al., The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains, Int J Infect Dis, vol.56, p.28163165, 2017.

, Geneva: World Health Organization, 2018.

, Report on Tuberculosis Research Funding Trends, 2005.

C. Lienhardt and P. Nahid, Advances in clinical trial design for development of new TB treatments: A call for innovation, PLoS Med, vol.2019, issue.3, p.1002769
URL : https://hal.archives-ouvertes.fr/inserm-02170758

, Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. Choice of control group and related issues in clinical trials (E10), 2000.

B. Freedman, Equipoise and the ethics of clinical research, N Engl J Med, vol.317, issue.3, p.3600702, 1987.

, Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update): World Health Organization, 2017.

, World Health Organization. WHO treatment guidelines for multidrug-and rifampicin-resistant tuberculosis, 2018 update. Geneva: World Health Organization, 2018.

S. Senn, Seven myths of randomisation in clinical trials, Stat Med, vol.32, issue.9, p.23255195, 2013.

M. T. Gler, V. Skripconoka, E. Sanchez-garavito, H. Xiao, J. L. Cabrera-rivero et al., Delamanid for Multidrug-Resistant Pulmonary Tuberculosis, N Engl J Med, vol.366, issue.23, p.22670901, 2012.

F. Von-groote-bidlingmaier, R. Patientia, E. Sanchez, V. Balanag, E. Ticona et al., Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrugresistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial, Lancet Respir Med. 2019. Epub, issue.18, pp.30426-30426, 2019.

A. H. Diacon, P. R. Donald, A. Pym, M. Grobusch, R. F. Patientia et al., Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance, Antimicrob Agents Chemother, vol.56, issue.6, p.22391540, 2012.

P. Central and P. , , p.3370813

A. H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee et al., The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis, N Engl J Med, vol.360, issue.23, p.19494215, 2009.

T. C. Bouton, P. Phillips, C. D. Mitnick, C. A. Peloquin, K. Eisenach et al., An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial, Trials, vol.18, issue.1, p.5702225, 2017.

E. Cox, L. Borio, and R. Temple, Evaluating Ebola therapies-the case for RCTs, N Engl J Med, vol.371, issue.25, pp.2350-2351, 2014.

A. J. Nunn, I. Rusen, A. Van-deun, G. Torrea, P. P. Phillips et al., Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial, Trials, vol.15, issue.1, p.4164715, 2014.

M. Cellamare, S. Ventz, E. Baudin, C. D. Mitnick, and L. Trippa, A Bayesian response-adaptive trial in tuberculosis: The endTB trial, Clin Trials, vol.14, issue.1, pp.17-28, 2017.

R. Moodley and T. R. Godec, Stream Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials, Eur Respir Rev, vol.25, issue.139, pp.29-35, 2016.

V. Prasad, A. Cifu, and J. P. Ioannidis, Reversals of established medical practices: evidence to abandon ship, JAMA, vol.307, issue.1, p.22215160, 2012.

J. D. Neaton, B. Grund, and D. Wentworth, How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know, Clinical Trials, p.1740774518764449, 2018.

, World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update: World Health Organization, 2011.

A. H. Diacon, A. Pym, M. P. Grobusch, J. M. De-los-rios, E. Gotuzzo et al., Multidrug-resistant tuberculosis and culture conversion with bedaquiline, N Engl J Med, vol.371, issue.8, pp.723-755, 2014.

, Guidance for Industry. Non-inferiority clinical trials to establish effectiveness: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2016.

C. Nimmo, M. Lipman, P. P. Phillips, T. Mchugh, A. Nunn et al., Shortening treatment of tuberculosis: lessons from fluoroquinolone trials, Lancet Infect Dis, vol.15, issue.2, pp.141-144, 2015.

E. W. Tiemersma, M. J. Van-der-werf, M. W. Borgdorff, B. G. Williams, and N. J. Nagelkerke, Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review, PLoS ONE, vol.6, issue.4, p.3070694, 2011.

S. Miyahara, G. Montepiedra, S. Kim, S. Evans, A. Gupta et al., Risk-Benefit Analyses Using Novel Methods in the A5279 Latent-TB Clinical Trial. The 49th Union World Conference on Lung Health, 2018.

A. J. Nunn, P. Phillips, and S. H. Gillespie, Design issues in pivotal drug trials for drug sensitive tuberculosis (TB), Tuberculosis, vol.88, p.18762156, 2008.

T. R. Fleming, Current issues in non-inferiority trials, Stat Med, vol.27, issue.3, p.17340597, 2008.

, Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. Statistical Principles for Clinical Trials (E9), 1998.

L. Mauri and D. Sr, Challenges in the Design and Interpretation of Noninferiority Trials, N Engl J Med, vol.377, issue.14, pp.1357-67, 2017.

, Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. Estimands and sensitivity analysis in clinical trials. E9(R1), 2017.

A. R. Laptook, S. Shankaran, J. E. Tyson, B. Munoz, E. F. Bell et al., Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With HypoxicIschemic Encephalopathy: A Randomized Clinical Trial, JAMA, vol.318, issue.16, p.5783566, 2017.

, Guidance for Industry. Adaptive designs for clinical trials of drugs and biologics (Draft guidance): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2018.

P. Phillips, S. H. Gillespie, M. Boeree, N. Heinrich, R. Aarnoutse et al., Innovative trial designs are practical solutions for improving the treatment of tuberculosis, J Infect Dis, vol.205, issue.2, 2012.

M. J. Boeree, N. Heinrich, R. Aarnoutse, A. H. Diacon, R. Dawson et al., High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis, vol.17, p.28100438, 2017.

J. Bowden and E. Glimm, Unbiased estimation of selected treatment means in two-stage trials, Biom J, vol.50, issue.4, p.18663760, 2008.

S. J. Mandrekar, M. W. An, and D. J. Sargent, A review of phase II trial designs for initial marker validation, Clin Trials, vol.36, issue.2, p.23665336, 2013.

P. Central and P. , , p.3779487

M. Y. Polley, B. Freidlin, E. L. Korn, B. A. Conley, J. S. Abrams et al., Statistical and practical considerations for clinical evaluation of predictive biomarkers, J Natl Cancer Inst, vol.105, issue.22, p.3888208, 2013.

S. J. Mandrekar and D. J. Sargent, Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges, J Clin Oncol, vol.27, issue.24, p.2734400, 2009.

V. R. Aber and A. J. Nunn, Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy, Bull Int Union Tuberc, vol.53, issue.4, p.387141, 1978.

W. Fox, Whither short-course chemotherapy?, Br J Dis Chest, vol.75, issue.4, p.7030377, 1981.

N. Alipanah, A. Cattamanchi, R. Menzies, P. C. Hopewell, R. E. Chaisson et al., Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis, Int J Tuberc Lung Dis, vol.20, issue.11, p.27776595, 2016.

M. Z. Imperial, P. Nahid, P. Phillips, G. R. Davies, K. Fielding et al., A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis, Nat Med, vol.24, issue.11, p.30397355, 2018.

G. J. Churchyard, A stratified approach to tuberculosis treatment, Nat Med, vol.24, issue.11, p.30401868, 2018.

P. Nahid, R. Savic, and P. Phillips, The CURE-TB Strategy Trial concept on stratified medicine trials in active TB, 2018.

E. D. Saad, X. Paoletti, T. Burzykowski, and M. Buyse, Precision medicine needs randomized clinical trials, Nat Rev Clin Oncol, vol.14, issue.5, p.28169302, 2017.

I. Ford and J. Norrie, Pragmatic Trials, N Engl J Med, vol.375, issue.5, pp.454-63, 2016.

M. Roland and D. J. Torgerson, What are pragmatic trials?, BMJ, vol.316, issue.7127, p.2665488, 1998.

K. Loudon, S. Treweek, F. Sullivan, P. Donnan, K. E. Thorpe et al., The PRECIS-2 tool: designing trials that are fit for purpose, BMJ, vol.350, p.25956159, 2015.

, The use of bedaquiline in the treatment of multidrug-resistant tuberculosis -Interim policy guidance. Geneva: World Health Organization, 2013.

, Rapid Communication: Key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB): World Health Organization, 2018.

J. D. Lundgren, A. G. Babiker, F. Gordin, S. Emery, and B. Grund, Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, N Engl J Med, vol.373, issue.9, p.4569751, 2015.

G. J. Churchyard, W. S. Stevens, L. D. Mametja, K. M. Mccarthy, V. Chihota et al., Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF, Lancet Glob Health, vol.3, issue.8, p.26187490, 2015.

N. Schluger, U. Karunakara, C. Lienhardt, T. Nyirenda, and R. Chaisson, Building clinical trials capacity for tuberculosis drugs in high-burden countries, PLoS Med, vol.4, issue.11, p.2062480, 2007.

M. Casenghi, S. T. Cole, and C. F. Nathan, New approaches to filling the gap in tuberculosis drug discovery, PLoS Med, vol.4, issue.11, p.2062479, 2007.

C. D. Mitnick, K. G. Castro, M. Harrington, L. V. Sacks, and W. Burman, Randomized trials to optimize treatment of multidrug-resistant tuberculosis, PLoS Med, vol.4, issue.11, p.2062482, 2007.

M. Rao, G. Ippolito, S. Mfinanga, F. Ntoumi, D. Yeboah-manu et al., Improving treatment outcomes for MDR-TB-novel host-directed therapies and personalised medicine of the future, Int J Infect Dis, vol.2019, p.30685590